dihydralazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antihypertensives, hydrazinephthalazine derivatives 884 484-23-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dihydralazine
  • dihydralazin
  • dihydrazinophthalazine
  • hypopresol
  • nepresol
  • nepresolin
  • nepressol
  • ophthazin
  • tonolysin
  • dihydralazine sulfate
  • dihydrallazine
1,4-Dihydrazinophthalazine. An antihypertensive agent with actions and uses similar to those of HYDRALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p354)
  • Molecular weight: 190.21
  • Formula: C8H10N6
  • CLOGP: -1.52
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 4
  • TPSA: 100.82
  • ALOGS: -2.30
  • ROTB: 0

Drug dosage:

DoseUnitRoute
75 mg O
25 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Hosey CM, Chan R, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class AAK1,ACVR1B,ACVR2A,ACVR2B,AKT2,AKT3,ALK,AURKA,AURKB,AURKC,AXL,BRAF,CAMK2B,CAMK2D,CDK1,CDK5,CDK7,CDK9,CHEK1,CLK4,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,EPHA2,EPHB4,ERBB2,FLT3,GRK1,GRK2,GRK3,GSK3B,IKBKB,IRAK1,ITK,JAK1,JAK2,KIT,MAP2K6,MAP3K1,MAP3K10,MAP3K11,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAP4K5,MAPK1,MAPK10,MAPK12,MAPK7,MAPK8,MAPK9,MAPKAPK2,MARK4,MELK,MET,MTOR,NTRK2,PAK4,PDK1,PDK2,PDPK1,PIK3CB,PIK3CD,PIM1,PIM2,PLK1,PRKAA1,PRKAA2,PRKCD,PRKDC,SGK1,SIK2,SIK3,STK10,STK33,SYK,TEK,TGFBR1,TNIK,TTK,ULK1,ULK2 86
kinase-selectivity-class ACVR2A,ACVR2B,AURKB,AXL,BRAF,CAMK2D,CDK9,DYRK1B,EIF2AK3,ERBB2,GRK2,MAP2K3,MAP2K6,MAP3K10,MAP3K21,MAPK7,MARK4,SGK1,SIK2,STK33,TEK,TTK,ULK1 23
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Patent ductus arteriosus 104.23 56.37 18 393 4551 90623485
Language disorder 64.16 56.37 11 400 2641 90625395
Premature baby 63.57 56.37 16 395 25061 90602975

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Shone complex 106.68 62.84 13 648 72 42620602
Ventricular septal defect 93.99 62.84 20 641 4379 42616295
Patent ductus arteriosus 86.90 62.84 18 643 3458 42617216
Atrial septal defect 82.28 62.84 20 641 7899 42612775
Product prescribing error 70.70 62.84 23 638 26089 42594585
Aorta hypoplasia 67.80 62.84 9 652 106 42620568
Supravalvular aortic stenosis 65.98 62.84 8 653 42 42620632

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product prescribing error 97.23 48.08 29 800 51302 110537168
Acute graft versus host disease in skin 68.91 48.08 16 813 10724 110577746
Product monitoring error 55.67 48.08 13 816 8914 110579556
Language disorder 54.51 48.08 11 818 3827 110584643
Mitral valve hypoplasia 54.08 48.08 6 823 30 110588440
Shone complex 54.08 48.08 6 823 30 110588440
Congenital aortic valve stenosis 53.91 48.08 6 823 31 110588439
Aorta hypoplasia 53.45 48.08 6 823 34 110588436
Congenital heart valve disorder 52.61 48.08 6 823 40 110588430
Coarctation of the aorta 49.68 48.08 6 823 69 110588401
Labelled drug-drug interaction medication error 48.71 48.08 15 814 29287 110559183
Gallbladder enlargement 48.37 48.08 9 820 2053 110586417

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C02DB01 CARDIOVASCULAR SYSTEM
ANTIHYPERTENSIVES
ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON
Hydrazinophthalazine derivatives
ATC C02LG01 CARDIOVASCULAR SYSTEM
ANTIHYPERTENSIVES
ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION
Hydrazinophthalazine derivatives and diuretics
ATC C02LG51 CARDIOVASCULAR SYSTEM
ANTIHYPERTENSIVES
ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION
Hydrazinophthalazine derivatives and diuretics
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D014665 Vasodilator Agents
CHEBI has role CHEBI:35674 antihypertensive agent

Related Drugs by ATC class:

C02DB Hydrazinophthalazine derivatives 3 drugs
cadralazineendralazinehydralazine
C02LG Hydrazinophthalazine derivatives and diuretics 2 drugs
hydralazinepicodralazine

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.51 Basic
pKa2 9.9 Basic
pKa3 4.95 Basic
pKa4 4.35 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
N0000167108 NUI
D07170 KEGG_DRUG
235959 RXNORM
C0012271 UMLSCUI
CHEBI:134841 CHEBI
CHEMBL35505 ChEMBL_ID
DB12945 DRUGBANK_ID
D004078 MESH_DESCRIPTOR_UI
10230 PUBCHEM_CID
245 INN_ID
PCU411F5L6 UNII
004347 NDDF
004348 NDDF
703113001 SNOMEDCT_US
703114007 SNOMEDCT_US
D006830 MESH_DESCRIPTOR_UI
CHEMBL2106266 ChEMBL_ID
7327-87-9 SECONDARY_CAS_RN

Pharmaceutical products:

None